Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 426 participants.

Also called NCT07614958

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 426 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07614958
  • EU CT 2025-524265-24-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07614958. Randomized; double masking; primary purpose treatment. Start 2026-05-06 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Acronym
MEDICI
Condition
Mixed Dyslipidemia
Condition
Hypercholesterolaemia
Intervention (Drug)
Obicetrapib 10 mg/Bempedoic Acid Placebo
Intervention (Drug)
Bempedoic Acid 180mg/Placebo Obicetrapib
Lead sponsor
A. Menarini International Licensing S.A. (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07614958
Content hash
81846704ad51776fbbe3e1a9913aa293b8a79d2121c3542838d6f9638494c8f6